BAA contract advanced analytical techniques for mixed polymer drug-delivery systems
Ended Definitive Contract Awarded Last action
- Contract number
- HHSF223201610091C
- Awardee
-
Akina, Inc. UEI WTBLC3LE13U1
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $548,834
Award facts
- Opportunity
-
- FDABAA1600122 Solicitation number
- Food and Drug Administration Broad Agency Announcement for the Advanced Research and Development of Regulatory Science Award Notice · Posted Feb 23, 2016
- Contract value 100% obligated
- $548,834.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 68 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- West Lafayette, IN, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $173,436 | |
| Original award | $375,398 |
About this award
This is a definitive, firm-fixed-price contract awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Akina, Inc., a minority-owned, for-profit, Asian-Pacific American manufacturer of research products and services. The $548,834 contract is for the development of advanced analytical techniques for mixed polymer drug-delivery systems, supporting the FDA's regulatory science and innovation goals. This contract, which has no set-aside designation, aims to advance product evaluation and post-market surveillance capabilities for complex long-acting injectable formulations, including miniaturized and injectable poly(lactide-co-glycolide) (PLGA) formulations. Akina, Inc. has also received a $320,000 Project Grant award from the National Institutes of Health National Institute on Drug Abuse to develop a 3-month injectable buprenorphine microparticle formulation for treating opioid use disorder.
Quick answers
Who was awarded contract HHSF223201610091C?
HHSF223201610091C was awarded to Akina, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 6, 2016.
How much is contract HHSF223201610091C worth?
The government has obligated $548,834 on HHSF223201610091C.
Was contract HHSF223201610091C competed?
The extent of competition for HHSF223201610091C was full and open competition. The government received 68 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award